Print

Pluristem Therapeutics (PSTI) Shares Slump A Day Before Phase 1/2 Study Results Are Released  
1/20/2014 8:34:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The share price of Pluristem Therapeutics Ltd. (Nasdaq:PSTI; TASE: PLTR) fell by 19.5% in morning trading on the Tel Aviv Stock Exchange (TASE) today, before partly recovering, without any announcement from the company. The volatility in share price comes a day before the company publishes the results of a clinical trial of its stem cell treatment for muscle injury. Pluristem's share price was down 8.3% by early afternoon on the TASE today, to NIS 14.42, after falling 0.9% on Nasdaq on Friday to $4.43, giving a market cap of $265 million.

Help employers find you! Check out all the jobs and post your resume.

//-->